Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. Nov. 22, 2017. Pierre Chauvineau.

Executive Summary

Check out what Boston Scientific's Pierre Chauvineau had to say about the US possibly being the firm's first go-to market for new products.

"If you were a company what would you do? If you have a market as large as the US, with one language [and] one regulation, and if you can get regulatory approval faster in the US, or at least at the same time as Europe, you'd want to invest in the US, not in Europe. We hope it isn't going to cause too much disruption in the technological innovation. That said, we do agree that we need quality products with quality outcomes – but there needs to be a fine balance." – Pierre Chauvineau, VP executive advisor, Boston Scientific

Click here for a free trial of Medtech Insight

Advertisement

Related Content

Exec Chat: From Cameron To Boston Scientific, Navigating Through CRM Challenges

Topics

Advertisement
UsernamePublicRestriction

Register

MT121795

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel